Search results

Radioisotopes are widely used in medicine, industry, and scientific research. New applications for radioisotopes are constantly being developed.

Discover the amazing world of nuclear science from your classroom. Join us for Meet an Expert, Nuclear Science Inquiry Skills, Junior Science, and Online Depth Study sessions for Chemistry, Physics and Investigating Science.

Australia’s Open Pool Australian Lightwater (OPAL) reactor is a state-of-the-art 20 megawatt multi-purpose reactor that uses low enriched uranium (LEU) fuel to achieve a range of  activities to benefit human health, enable research to support a more sustainable environment and provide innovative solutions for industry.

ANSTO recently hosted a public Ask Us Anything event on nuclear medicine, sharing information on how we safely manufacture and distribute nuclear medicine across Australia each week to hundreds of hospitals and clinics.

The new facility will be built around a product line of ANSTO’s design – a new Technetium-99m generator – that will enable greater process automation than is possible with existing technology, leading to improvements in efficiency, quality and importantly the highest levels of production safety.

Developed by ANSTO’s predecessor the Australian Atomic Energy Commission (known as the AAEC) in the late 1960s, the Technetium-99m Generator revolutionised nuclear medicine imaging in Australia by enabling imaging procedures to be performed not only in major capital cities but throughout regional and rural Australia.

ANSTO health researchers have expertise in the development of radioactive probes and imaging techniques.

Whilst at ANSTO’s Australian Synchrotron today, Prime Minister Scott Morrison announced new funding for the Australian Precision Medicine Enterprise (APME) Project. The Australian Government will contribute $23m in grant funding under the Manufacturing Collaboration Stream of the Modern Manufacturing Initiative (MMI) towards the $71.2m project.

ANSTO manufacture and supply a range of radiopharmaceuticals, radiochemicals, kits and accessories for use in research, industry and the health sector.

ANSTO is a major supplier of Australia’s radioactive isotopes used in nuclear medicine, delivering around 10,000 patient doses each week.  Health-based research and development in Australia and overseas also benefit greatly from ANSTO’s unique capabilities and expertise in the detection, diagnosis and treatment of disease using nuclear and accelerator infrastructure.​

Radioactive phosphorous for implantable medical device to treat pancreatic cancer in global clinical trial

ANSTO has safely managed its radioactive waste for over 60 years. Waste is managed in accordance with national and international standards.

This joint initiative at ANSTO has developed a new capability: solid surface radiolabelling to evaluate Auger emitting sources for next-generation targeted therapy.

The nuclear medicine community has welcomed the Australian Government’s decision to provide $30 million in funding to ANSTO for the design of a new nuclear medicine manufacturing facility.